Menin Inhibitor in Type 1 Diabetes
Sector
Biotech
Company
Emerging Biotech
Therapeutic Area
Metabolic
Treatment Modality
Small Molecule
Product Stage
Clinical
Expertise
Scientific Communications
An emerging biotech is advancing a first-in-class menin inhibitor with potential to regenerate pancreatic β-cells and restore endogenous insulin production in type 1 diabetes. For a program addressing one of the most entrenched unmet needs in metabolic disease, the challenge was not only to communicate compelling preclinical data but to frame the therapy credibly against the backdrop of existing insulin-centric treatment paradigms.
Situation
An emerging biotech is advancing a first-in-class menin inhibitor with potential to regenerate pancreatic β-cells and restore endogenous insulin production in type 1 diabetes. For a program addressing one of the most entrenched unmet needs in metabolic disease, the challenge was not only to communicate compelling preclinical data but to frame the therapy credibly against the backdrop of existing insulin-centric treatment paradigms.
Situation
Approach
Our work focused on developing a clear scientific lexicon to explain the role of menin biology in β-cell regeneration and contextualize its relevance for type 1 diabetes pathophysiology. We supported the creation of publication plans, abstracts, and congress materials that highlighted preclinical results in autoimmune settings, while ensuring communications were grounded in scientific credibility and aligned with regulatory expectations. To prepare for eventual clinical readouts, we also built MSL briefing resources and data toolkits to enable consistent communication across internal and external stakeholders.
Our work focused on developing a clear scientific lexicon to explain the role of menin biology in β-cell regeneration and contextualize its relevance for type 1 diabetes pathophysiology. We supported the creation of publication plans, abstracts, and congress materials that highlighted preclinical results in autoimmune settings, while ensuring communications were grounded in scientific credibility and aligned with regulatory expectations. To prepare for eventual clinical readouts, we also built MSL briefing resources and data toolkits to enable consistent communication across internal and external stakeholders.
Approach
Results
This approach positioned the menin program as a differentiated, disease-modifying candidate in type 1 diabetes. By translating complex biology into clear, credible communications, the company elevated awareness among KOLs, advocacy groups, and the broader scientific community—laying the foundation for confidence ahead of first-in-human studies
This approach positioned the menin program as a differentiated, disease-modifying candidate in type 1 diabetes. By translating complex biology into clear, credible communications, the company elevated awareness among KOLs, advocacy groups, and the broader scientific community—laying the foundation for confidence ahead of first-in-human studies
Situation
An emerging biotech is advancing a first-in-class menin inhibitor with potential to regenerate pancreatic β-cells and restore endogenous insulin production in type 1 diabetes. For a program addressing one of the most entrenched unmet needs in metabolic disease, the challenge was not only to communicate compelling preclinical data but to frame the therapy credibly against the backdrop of existing insulin-centric treatment paradigms.
Approach
Our work focused on developing a clear scientific lexicon to explain the role of menin biology in β-cell regeneration and contextualize its relevance for type 1 diabetes pathophysiology. We supported the creation of publication plans, abstracts, and congress materials that highlighted preclinical results in autoimmune settings, while ensuring communications were grounded in scientific credibility and aligned with regulatory expectations. To prepare for eventual clinical readouts, we also built MSL briefing resources and data toolkits to enable consistent communication across internal and external stakeholders.
Results
This approach positioned the menin program as a differentiated, disease-modifying candidate in type 1 diabetes. By translating complex biology into clear, credible communications, the company elevated awareness among KOLs, advocacy groups, and the broader scientific community—laying the foundation for confidence ahead of first-in-human studies
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.